A team of researchers has identified how misfolded proteins quietly sabotage the pancreatic cells that produce insulin, offering a potential new angle for treating diabetes before the disease takes hold.
The finding centers on proinsulin, the raw material cells use to manufacture insulin. When proinsulin fails to fold into the correct three-dimensional shape, it accumulates inside beta cells, the insulin-producing workhorses of the pancreas. This toxic buildup damages the cells themselves, contributing to the progressive failure that defines diabetes. The discovery appears in the Proceedings of the National Academy of Sciences and was conducted by researchers at Sanford Burnham Prebys Medical Discovery Institute and the University of Michigan.
Protein folding is as critical as it sounds. Just as paper must form precise shapes to become origami, proteins require exact configurations to function. When the machinery that guides this folding breaks down, cells begin to fail.
The Partner Proteins That Do the Heavy Lifting
Scientists already knew that a protein called binding immunoglobulin protein, or BiP, played a starring role in keeping proinsulin properly folded. What remained a mystery was how BiP actually did the job and what other proteins helped it work.
The research team, led by Randal J. Kaufman at Sanford Burnham Prebys, targeted one particular partner protein called p58IPK. When they eliminated p58IPK from lab cell lines, misfolded proinsulin piled up. Mice engineered to skip p58IPK produced less insulin overall. The message was clear: this cochaperone mattered.
But here is where the story gets interesting. When researchers restored p58IPK alone to the cells, the improvements were modest. The real magic happened only when both BiP and p58IPK worked together at normal levels.
"Like a single tennis player trying to play a doubles match, we found that BiP cannot just go it alone in maintaining the proper folding of proinsulin," said Insook Jang, the lead scientist on the study.
This finding has major implications. It means that boosting just one protein is not enough. The cells need the right team of proteins operating in sync, each doing its part to prevent proinsulin misfolding and eliminate mistakes that do occur.
The team also identified additional partner proteins involved in the folding, transport, and quality control of proinsulin. The full picture of how all these proteins coordinate remains incomplete, but the research charts a clearer path forward.
A Window for Early Intervention
Current diabetes treatments take an indirect approach. They help cells absorb more glucose or spur the pancreas to release more insulin. None directly address the protein-folding problem at the root of beta cell failure.
"If we can learn how to influence the coordinated activity of BiP as a key regulator of proinsulin folding, we may find a promising treatment strategy for intervening early to prevent or reduce damage to insulin-producing cells," Kaufman said.
The potential is enormous. If researchers can find drugs that strengthen the cellular folding machinery before diabetes becomes full-blown, they might stop the disease in its tracks during the prediabetic stage, when the beta cells are just beginning to struggle.
The research opens a window into what happens inside beta cells as prediabetes advances toward type 2 diabetes. Misfolded proteins do not announce themselves. They accumulate silently, and by the time someone gets a diabetes diagnosis, significant damage has already occurred. Understanding this hidden process could change how doctors intervene and when.
Author Jessica Williams: "This work nails down the choreography of an invisible disaster happening inside millions of people's pancreases every day, and it suggests we might finally have a way to stop it."
Comments